Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revlimid lenalidomide: Phase III data

In a double-blind, U.S. Phase III trial (S0232) in 198 newly diagnosed MM patients, the overall response rate was 85.3%

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE